DNLI Q1 2021 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+119.8% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$71M-898.9% margin

Net Income

-$70M-884.0% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

-97.5%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$53M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$443M

Stockholders' Equity

$1.1B

Cash & Equivalents

$435M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$4M	+119.8%
Gross Profit	$8M	$4M	+119.8%
Operating Income	-$71M	-$60M	-18.8%
Net Income	-$70M	-$57M	-23.4%

Revenue Segments

Alzheimer's Disease Services

$3M100%